Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival

医学 内科学 不利影响 血液学 不良事件通用术语标准 免疫疗法 肝炎 癌症
作者
Abdul Miah,Gabriel Tinoco,Songzhu Zhao,Lai Wei,Andrew Johns,Sandip Pravin Patel,Mingjia Li,Madison Grogan,Gabrielle Lopez,Marium Husain,Rebecca Hoyd,Khalid Mumtaz,Alexa Meara,Erin M. Bertino,Kari Kendra,Daniel Spakowicz,Gregory A. Otterson,Carolyn J. Presley,Dwight H. Owen
出处
期刊:Journal of Cancer Research and Clinical Oncology [Springer Science+Business Media]
卷期号:149 (5): 2235-2242 被引量:21
标识
DOI:10.1007/s00432-022-04340-3
摘要

Immune checkpoint inhibitors (ICIs) are associated with a unique set of immune-related adverse events (irAEs). Few studies have evaluated the risk factors and outcomes of patients who develop ICI-induced hepatitis (ICIH).We utilized an institutional database of patients with advanced cancers treated with ICI to identify patients with ICIH. irAEs were graded using the Common Terminology Criteria for Adverse Events v4. Overall survival (OS) was calculated from the date of ICI to death from any cause or the date of the last follow-up. OS with 95% confidence intervals were estimated using the Kaplan-Meier method and stratified by the occurrence of ICIH.We identified 1096 patients treated with ICI. The most common ICIs were PD1/L1 (n = 774) and CTLA-4 inhibitors (n = 195). ICIH occurred among 64 (6%) patients: severity was < grade 3 in 30 and ≥ grade 3 in 24 patients (3.1% overall). Median time to ICIH was 63 days. ICIH was more frequent in women (p = 0.038), in patients treated with combination ICIs (p < 0.001), and when given as first-line therapy (p = 0.018). Occurrence of ICIH was associated with significantly longer OS, median 37.0 months (95% CI 21.4, NR) compared to 11.3 months (95% CI 10, 13, p < 0.001); there was no difference in OS between patients with ≥ grade 3 ICIH vs grade 1-2.Female sex, combination immunotherapy, and the first line of immunotherapy were associated with ICIH. Patients with ICIH had improved clinical survival compared to those that did not develop ICIH. There is a need for prospective further studies to confirm our findings.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
汉堡包应助NOTHING采纳,获得10
1秒前
SYLH应助科研通管家采纳,获得50
1秒前
quhayley应助科研通管家采纳,获得10
1秒前
爆米花应助科研通管家采纳,获得10
1秒前
坦率的匪应助科研通管家采纳,获得10
2秒前
田様应助科研通管家采纳,获得10
2秒前
SYLH应助科研通管家采纳,获得50
2秒前
orixero应助科研通管家采纳,获得10
2秒前
SYLH应助科研通管家采纳,获得50
2秒前
思源应助科研通管家采纳,获得10
2秒前
2秒前
隐形曼青应助科研通管家采纳,获得10
2秒前
czh应助科研通管家采纳,获得10
2秒前
赘婿应助科研通管家采纳,获得10
2秒前
华仔应助科研通管家采纳,获得10
2秒前
科研通AI2S应助科研通管家采纳,获得10
2秒前
3秒前
SYLH应助科研通管家采纳,获得50
3秒前
大模型应助科研通管家采纳,获得10
3秒前
3秒前
斯文败类应助Keyl采纳,获得10
3秒前
褪黑素应助科研通管家采纳,获得10
3秒前
完美世界应助科研通管家采纳,获得10
3秒前
3秒前
3秒前
3秒前
3秒前
3秒前
3秒前
3秒前
3秒前
3秒前
3秒前
努力科研霸王龙完成签到 ,获得积分10
4秒前
nns关闭了nns文献求助
4秒前
田様应助jiabaoyu采纳,获得10
5秒前
脑洞疼应助林林林林采纳,获得10
5秒前
xiaoxiao完成签到,获得积分10
5秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988732
求助须知:如何正确求助?哪些是违规求助? 3531027
关于积分的说明 11252281
捐赠科研通 3269732
什么是DOI,文献DOI怎么找? 1804764
邀请新用户注册赠送积分活动 881869
科研通“疑难数据库(出版商)”最低求助积分说明 809021